UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors.

Kaufmann H.SourceMount Sinai School of Medicine, New York, NY 10029, USA. Horacio.Kaufmann@mssm.edu
Journal of neural transmission. Supplementum.J Neural Transm Suppl.2006;(70):477-84.
In the 1950s it was found that an artificial aminoacid, 3,4-threo-dihydroxyphenylserine (DOPS), was converted to norepinephrine (NE) in a single step by the enzyme L-aromatic amino acid decarboxylase (AADC), bypassing the need for the rate limiting enzyme dopamine beta hydroxylase. Trying to replica
PMID 17017570

DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.

Birkmayer W, Birkmayer G, Lechner H, Riederer P.AbstractParkinsonian patients with orthostatic hypotension and dizziness due to usual antiparkinson therapy have been treated with the precursor amino-acid of noradrenaline, DL-3,4-threo-dihydroxyphenylserine (DL-3,4-threo-DOPS). Oral and intravenous administration improved these side effects significantly. A combined treatment of L-dopa, peripheral decarboxylase inhibitor and DL-3,4-threo-DOPS seems to be of benefit with respect to akinesia and orthostatic hypotension.
Journal of neural transmission.J Neural Transm.1983;58(3-4):305-13.
Parkinsonian patients with orthostatic hypotension and dizziness due to usual antiparkinson therapy have been treated with the precursor amino-acid of noradrenaline, DL-3,4-threo-dihydroxyphenylserine (DL-3,4-threo-DOPS). Oral and intravenous administration improved these side effects significantly.
PMID 6420517